| Unique ID issued by UMIN | UMIN000056394 |
|---|---|
| Receipt number | R000060075 |
| Scientific Title | Effects of tranexamic acid on sore throat pain associated with acute upper respiratory tract infection: a randomized, controlled trial |
| Date of disclosure of the study information | 2024/12/08 |
| Last modified on | 2026/02/04 15:14:02 |
Effects of tranexamic acid on sore throat pain associated with acute upper respiratory tract infection: a randomized, controlled trial
Effects of tranexamic acid on sore throat pain associated with common cold
Effects of tranexamic acid on sore throat pain associated with acute upper respiratory tract infection: a randomized, controlled trial
Effects of tranexamic acid on sore throat pain: a randomized, controlled trial
| Japan |
upper respiratory tract infection
| Medicine in general |
Others
YES
We investigate the efficacy of tranexamic acid on sore throat pain associated with acute URTI compared with a placebo.
Efficacy
The proportion of patients with sore throat score more than moderate level between 2 hours after tranexamic acid is taken.
Primary outcome is the difference on sore throat VAS scale between 10 minutes after tranexamic acid is taken.
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
| Medicine |
Patients receive 1g of 50% tranexamic acid preparation of with a cup of water.
Patients receive 1g placebo (lactose), desolved with a cup of water.
| 18 | years-old | <= |
| 65 | years-old | > |
Male and Female
Patients of upper respiratory tract infections with a complaint of sore throat, who visited a general internal medicine department office in the Akashi medical center hospital from November 2023 to October 2024 were registered.
Patients with allergy to tranexamic acid and lactose, pregnant patients or patients with possibility of pregnancy, breastfeeding patients, patients who take tranexamic acid, patients who were unable to participate the study because of dementia, visual impairment and unable to answer, or complete the study form.
80
| 1st name | Naoto |
| Middle name | |
| Last name | Ishimaru |
Akashi Medical Center
Department of General Internal Medicine
6740063
743-33 Yagi, Ohkubo-cho, Akashi, Hyogo 674-0063, Japan
0789361101
maru-tkb@umin.ac.jp
| 1st name | Naoto |
| Middle name | |
| Last name | Ishimaru |
Akashi Medical Center
Department of General Internal Medicine
6740063
743-33 Yagi, Ohkubo-cho, Akashi, Hyogo 674-0063, Japan
0789361101
maru-tkb@umin.ac.jp
Akashi Medical Center
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Institutional Review Board of Akashi Medical Center
743-33 Yagi, Ohkubo-cho, Akashi, Hyogo 674-0063, Japan
0789361101
tani.saori@aijinkai-group.com
NO
| 2024 | Year | 12 | Month | 08 | Day |
Published
https://onlinelibrary.wiley.com/doi/abs/10.1002/jgf2.70097
41
We analyzed the 17 participants assigned to each group (total = 34). The groups were not significantly different in the proportion of patients whose sore throat had a moderate or greater impact on their day-to-day life (TXA 41.2% vs. placebo 47.1%; p = 1.00). Similarly, they did not significantly differ in mean change of sore throat score on VAS within 30 min (TXA 17.3 vs. placebo 13.1; p = 0.49). No side effects were reported.
| 2026 | Year | 02 | Month | 04 | Day |
| 2026 | Year | 01 | Month | 03 | Day |
Completed
| 2023 | Year | 10 | Month | 28 | Day |
| 2023 | Year | 10 | Month | 18 | Day |
| 2023 | Year | 11 | Month | 06 | Day |
| 2025 | Year | 03 | Month | 31 | Day |
| 2024 | Year | 12 | Month | 08 | Day |
| 2026 | Year | 02 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060075